GlassScriptPhysician profile
Paula M Weaver
NPI 1851840706
$3,407.27
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,860 · 2022: $887 · 2023: $599 · 2024: $61.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $921.80 | 2021 | |
| Abbvie INC. | $443.58 | 2021-2024 | |
| Collegium Pharmaceutical, INC. | $396.12 | 2021-2023 | Xtampza, Belbuca |
| Biodelivery Sciences International, INC. | $160.41 | 2021 | |
| Amgen INC. | $151.36 | 2021-2022 | |
| Lundbeck LLC | $140.37 | 2022-2023 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $132.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.31 | 2022-2023 | Relistor |
| Medtronic, INC. | $106.71 | 2022-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Eisai INC. | $100.23 | 2021 | |
| Arbor Pharmaceuticals, INC. | $92.39 | 2021-2022 | |
| Pfizer INC. | $80.12 | 2021-2023 | |
| Redhill Biopharma INC. | $79.38 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $55.34 | 2023 | Trudhesa |
| Virtus Pharmaceuticals LLC | $53.16 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $47.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $44.20 | 2023 | Quviviq |
| Grt US Holding, INC. | $40.93 | 2021 | |
| Allergan, INC. | $35.27 | 2021 | |
| Upsher-Smith Laboratories LLC | $25.50 | 2021-2023 | |
| Averitas Pharma INC. | $23.83 | 2023 | Qutenza |
| Relievant Medsystems, INC. | $23.23 | 2021-2022 | |
| Tersera Therapeutics LLC | $21.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.37 | 2021 | |
| International Rehabilitative Sciences, INC | $16.19 | 2023 | Rs 4i Plus Sequential Stimulator |
| Teva Pharmaceuticals USA, INC. | $15.69 | 2022 | |
| Horizon Therapeutics Plc | $14.97 | 2022 | |
| Mdd US Operations, LLC | $14.07 | 2021 | |
| Indivior INC. | $13.50 | 2021 | |
| Nevro Corp. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.